Figure 8. MF286 increases insulin secretion in vivo. (A) A structural diagram of MF286. (B) Secreted insulin concentrations from MIN6 cells after treatment with chemical compounds after low (2.2 mM) or high (22 mM) glucose stimulation. The molar concentrations of each compound, which correspond to experimental concentrations (3, 10, and 30 µg/ml), were indicated. The data are representative of three independent experiments. (C) Survival curves of MIN6 cells after treatment with chemical compounds. (D) SPR measuring MF286 or DS565-8 binding to SNAP23 or SNAP25. DS565-8 was used as a negative control. (E) Secreted insulin concentrations from isolated islets after MF286 treatments after low (2.8 mM) or high (13.9 mM) glucose stimulation. The data are representative of three independent experiments. Data are mean ± SEM. Significance was calculated by the two-tailed paired Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 8.

MF286 increases insulin secretion in vivo. (A) A structural diagram of MF286. (B) Secreted insulin concentrations from MIN6 cells after treatment with chemical compounds after low (2.2 mM) or high (22 mM) glucose stimulation. The molar concentrations of each compound, which correspond to experimental concentrations (3, 10, and 30 µg/ml), were indicated. The data are representative of three independent experiments. (C) Survival curves of MIN6 cells after treatment with chemical compounds. (D) SPR measuring MF286 or DS565-8 binding to SNAP23 or SNAP25. DS565-8 was used as a negative control. (E) Secreted insulin concentrations from isolated islets after MF286 treatments after low (2.8 mM) or high (13.9 mM) glucose stimulation. The data are representative of three independent experiments. Data are mean ± SEM. Significance was calculated by the two-tailed paired Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal